Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Current Quarter	$0.5	Next Quarter	$0.53
Current Year	$2.35	Next Year	$2.38
QoQ Growth	+6.0%	YoY Growth	+1.3%
3Y EPS CAGR	+53.7%	Target Price	$34.50
Consensus	Buy	Upside	+47.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CPRX	$23.45	+2.99%	698.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CPRX	$23.45	+3.0%	698.00K
3
4
5
6

CPRX

CPRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Catalyst Pharmaceuticals Inc. Data in Excel

Get Catalyst Pharmaceuticals Inc. Data in Excel